Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Evusheld Wins EU Marketing Nod For Preventing COVID-19

If Approved Evusheld Will Become The EU’s Eighth COVID-19 Treatment

Executive Summary

The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.

You may also be interested in...



Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval

The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.

Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls

The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.

ERC Not Giving Up On Glioma Immunotherapy In EU

ERC Belgium has pledged to collect more data to convince the European Medicines Agency that Sitoiganap merits approval. Meanwhile, UGA Biopharma said it would address the agency’s objections over its biosimilar version of eptacog alfa.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel